Onward Medical N.v. · EURONEXT:ONWD
Onward Medical — H1 2026 Earnings Presentation
21 slides from Onward Medical's earnings presentation, Sep 9, 2026
Slide 1: Investor Webcast 2026 Half Year Results
Investor Webcast 2026 Half Year Results September 9, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This Presentation may include statements, including the Company’s financial and operational medium-term objectives, that may be deemed to be “forward-looking statements”. These forward- looking statements may be identified by the use of forward-looking terminology, includi
Slide 3: Speaking Today
Speaking Today Dave Marver Ali Kiboro Shari O’Quinn Sean Sciara Chief Executive Officer Chief Financial Officer Chief Clinical, Chief Commercial Officer Regulatory & Quality Officer September 2026 Webcast 3
Slide 4: 1H 2026 Business Updates
1H 2026 Business Updates
Slide 5: 1H & YTD Highlights
Strong execution and advancements across 1H & YTD our business Highlights Commercial traction 159 ARCEX Systems were sold or supplied via paid evaluation in 1H 2026 (5X increase YoY); ARCEX Systems available in over 130 US clinics and 150 clinics worldwide in 1H Empower BP global pivotal study o Ach
Slide 6: September 2026 Webcast
September 2026 Webcast 6
Slide 7: ARC EX Commercial Uptake
159 ARCEX Systems sold or under paid ARCEX Commercial evaluation in 1H 2026 Uptake # of units supplied 89 units > 130 US clinics 70 units penetrated 47 units > 150 clinics 40 units globally 20 units 10 units Q1 Q2 Q3 Q4 Q1 Q2 2025 2026 Limited US clinic Broad US clinic US home and launch commerciali
Slide 8: September 2026 Webcast
September 2026 Webcast 8
Slide 9: EMPOWER BP Update
22 participants enrolled across 14 EMPOWER BP active clinical sites Update 22 14 participants enrolled clinical sites actively recruiting September 2026 Webcast 9
Slide 10: ARC IM Blood Pressure Roadmap
Interim analysis on track for spring 2027; launch on track ARCIM Blood Pressure for late 2028 Roadmap Pivotal trial & commercial launch 2026 2027 2028 2029 Enrollment and primary endpoint completion Follow-up Interim analysis Submission & approval Anticipated commercial launch September 2026 Webcast
Slide 11: EIGER Study Implant
First successful implant in new clinical EIGER Study feasibility study evaluating ARCIM mobility after SCI Implant o EIGER study will assess the safety and preliminary effectiveness of the ARCIM System in up to 12 participants to restore mobility after both subacute and chronic SCI o EIGER is the fi
Slide 12: New Equity Financing
Successfully raised over €40M in new New Equity equity capital to fuel growth Financing o Financing included €25M investment from EQT Life Sciences o Strong demand from existing and new high-quality, long-only and sector specialist investors o Cash runway extends into Q1 2028 September 2026 Webcast
Slide 13: Debt Refinancing
Replaced existing loan with up to €50M Debt Refinancing debt facility from BlackRock o BlackRock has replaced Runway Growth Capital LLC as the Company's lender o €20M was drawn at closing, with access to additional tranches as we grow ARCEX revenue and advance toward commercialization of our investi
Slide 14: 2026 Half Year Results
2026 Half Year Results
Slide 15: Half Year 2026 Financial Review
Revenue growth following commercial launch of ARCEX Half Year 2026 Financial Review EUR Million For the six-month period ended, 30 June HY 2026 HY 2025 Total Revenues & Other Incomes 4.2 1.2 Cost of Goods Sold (1.3) (0.2) Gross Profit 2.9 1.0 Research & Development Expenses (6.0) (5.8) Clinical & Re
Slide 16: Half Year 2026 Cash Update
€4.2M in revenue and cash balance of Half Year 2026 €81.5M as of June 30, 2026 Cash Update Burn Current Cash Revenue €26.0M2 used Balance €4.2M in 1H 20261 during 1H 2026 €81.5M net cash3 as of 30 Jun 2026 1Revenue includes grant and other income, 2 Cash burn excludes proceeds from the April 2026 fu
Slide 17: 2026 Outlook
2026 Outlook
Slide 18: Upcoming Milestones and News Flow
Several important catalysts expected in the next 12 months Upcoming Milestones ARCEX ARCIM ARCBCI and News Flow ARCEX ARCEX ARCEX ARCEX First commercial clinic First commercial home First commercial clinic First commercial home sale (EU) use sale (US) sale (ROW) use sale (EU) Hand sensation & Hand s
Slide 19: Q&A
Q&A
Slide 20: Thank you!
Thank you! 20
Slide 21: Slide 21